Allegro to start production of osteoarthritis hydrogel as it prepares for clinical trialsLiege, Belgium – 9 January 2026 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology treatments for degenerative joint disease, will officially launch production of its first microparticle hydrogel after a ceremonial opening of its cleanroom manufacturing facility on 9 January 2026. After an investment worth multiple millions of euros, the state-of-the art facility enables annual production of a million prefilled syringes per year. The production will amongst others supply partner American Regent with Synoglide™, a novel treatment for osteoarthritis in the equine market, which has been launched recently in the US, for commercialization in veterinary markets worldwide.
Allegro showcases superior shock-absorbing capacity of injectable hydrogel for osteoarthritis at CellMechLiege, Belgium – 7 October 2025 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, today announces new research showing superior shock-absorbing capacities of its Hydrocelin injectable hydrogel to treat osteoarthritis, compared to four market leading hydrogels. The company presented the results in a poster at the CellMech conference in Louvain, Belgium, last week. The results also showed that Hydrocelin significantly improved the shock-absorbing properties of pathological equine synovial fluid in mechanical testing.
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studiesLiege, Belgium – 4 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing a transformative nanotechnology-based treatment for degenerative joint disease, announced today that hydrocelin (ALG-001), its lead injectable microparticle hydrogel, has been found safe in three preclinical studies. The studies found no signs of pyrogenicity, irritation or delayed sensitization in the test groups, strengthening hydrocelin’s safety profile after two earlier preclinical studies announced in December. Allegro intends to launch a multi-center pivotal trial in osteoarthritis patients in Belgium later this year.
Allegro’s osteoarthritis injectable shock absorbing gel demonstrates preclinical safetyLiege, Belgium – 11 December 2024 (07:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based devices for degenerative joint disease, today announced that its injectable microparticle gel, hydrocelin, has demonstrated favorable safety in two preclinical studies. The gel contains cross-linked microparticles that act as tiny shock absorbers in the synovial fluid. This reduces the force on sensitive nerve endings to provide immediate pain relief and starts to protect cartilage. Allegro intends to advance hydrocelin into multi-center pivotal clinical studies in osteoarthritis patients in 2025.
